Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H11FO5 |
| Molecular Weight | 182.1472 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O
InChI
InChIKey=AOYNUTHNTBLRMT-SLPGGIOYSA-N
InChI=1S/C6H11FO5/c7-3(1-8)5(11)6(12)4(10)2-9/h1,3-6,9-12H,2H2/t3-,4+,5+,6+/m0/s1
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. | 2010-08 |
|
| Hypermetabolism in patients with dementia with Lewy bodies. | 2010-07 |
|
| Importance of the gating segment in the substrate-recognition loop of pyranose 2-oxidase. | 2010-07 |
|
| Targeted therapies in renal cell cancer: recent developments in imaging. | 2010-06 |
|
| Effects of low-field magnetic stimulation on brain glucose metabolism. | 2010-06 |
|
| Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. | 2010-04-20 |
|
| Primary hepatic schwannoma mimicking malignancy on fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography. | 2010-03 |
|
| Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. | 2010-02-15 |
|
| The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. | 2010-01 |
|
| Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT. | 2009-12 |
|
| F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound. | 2009-08 |
|
| Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. | 2009-07 |
|
| Chemical approaches to perturb, profile, and perceive glycans. | 2009-06-16 |
|
| Positive correlation between serum liver enzyme levels and standard uptake values of liver on FDG-PET. | 2009-03-10 |
|
| Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. | 2009-03 |
|
| The role of FDG-PET in distinguishing between septic and aseptic loosening in hip prosthesis: a review of literature. | 2009-02 |
|
| Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state. | 2009-02 |
|
| Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging. | 2009-01 |
|
| Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography. | 2008-12-01 |
|
| Potential value of quantitative analysis of cerebral PET in early cognitive decline. | 2008-11-13 |
|
| The inhibitory effect of 2-halo derivatives of D-glucose on glycolysis and on the proliferation of the human malaria parasite Plasmodium falciparum. | 2008-11 |
|
| Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. | 2008-11 |
|
| Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). | 2008-10-17 |
|
| Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus. | 2008-10 |
|
| Imaging in cutaneous melanoma. | 2008-10 |
|
| FDG uptake, a surrogate of tumour hypoxia? | 2008-08 |
|
| Synthesis and cytotoxic properties of new fluorodeoxyglucose-coupled chlorambucil derivatives. | 2008-05-01 |
|
| Simultaneous analysis of FDG, ClDG and Kryptofix 2.2.2 in [18F]FDG preparation by high-performance liquid chromatography with UV detection. | 2008-02 |
|
| Pulmonary echinococcosis mimicking multiple lung metastasis of breast cancer: the role of fluoro-deoxy-glucose positron emission tomography. | 2008-01-21 |
|
| The utility of FDG-PET in the preoperative staging of esophageal cancer. | 2008 |
|
| Combined approach of perioperative 18F-FDG PET/CT imaging and intraoperative 18F-FDG handheld gamma probe detection for tumor localization and verification of complete tumor resection in breast cancer. | 2007-12-21 |
|
| Prognostic Value of FDG-PET in patients with oropharyngeal carcinoma treated with concurrent chemoradiotherapy. | 2007-11-16 |
|
| Cervical node metastasis as the first sign of cancer of the caecum. | 2007-11-02 |
|
| Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. | 2007-11 |
|
| The role of PET/CT for evaluating breast cancer. | 2007-10-10 |
|
| When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy? | 2007-10 |
|
| Stereotactic cortical resection in non-lesional extra-temporal partial epilepsy. | 2007-10 |
|
| Accessing the aortopulmonary window (#5) and the paraaortic (#6) lymph nodes in patients with non-small cell lung cancer. | 2007-09 |
|
| Case report: PET/CT, a cautionary tale. | 2007-08-03 |
|
| F-18 FDG PET in detecting uterine leiomyoma. | 2007-06-10 |
|
| FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model. | 2007-06-08 |
|
| Nuclear medicine in the rehabilitative treatment evaluation in stroke recovery. Role of diaschisis resolution and cerebral reorganization. | 2007-06 |
|
| Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. | 2007-03 |
|
| Hypertrophic cardiomyopathy complicated by left ventricular apical necrosis and aneurysm in a young man: FDG-PET findings. | 2007-03 |
|
| A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. | 2007-03 |
|
| Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. | 2007-02-01 |
|
| Gastric distension by ingesting food is useful in the evaluation of primary gastric cancer by FDG PET. | 2007-02 |
|
| Kidney modelling for FDG excretion with PET. | 2007 |
|
| Structural basis for substrate binding and regioselective oxidation of monosaccharides at C3 by pyranose 2-oxidase. | 2006-11-17 |
|
| F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. | 2006-09 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ZO2JV75L55
Created by
admin on Mon Mar 31 17:47:33 GMT 2025 , Edited by admin on Mon Mar 31 17:47:33 GMT 2025
|
PRIMARY | |||
|
100000141745
Created by
admin on Mon Mar 31 17:47:33 GMT 2025 , Edited by admin on Mon Mar 31 17:47:33 GMT 2025
|
PRIMARY | |||
|
Fludeoxyglucose
Created by
admin on Mon Mar 31 17:47:33 GMT 2025 , Edited by admin on Mon Mar 31 17:47:33 GMT 2025
|
PRIMARY | |||
|
1272907
Created by
admin on Mon Mar 31 17:47:33 GMT 2025 , Edited by admin on Mon Mar 31 17:47:33 GMT 2025
|
PRIMARY | |||
|
DTXSID701311592
Created by
admin on Mon Mar 31 17:47:33 GMT 2025 , Edited by admin on Mon Mar 31 17:47:33 GMT 2025
|
PRIMARY | |||
|
29702-43-0
Created by
admin on Mon Mar 31 17:47:33 GMT 2025 , Edited by admin on Mon Mar 31 17:47:33 GMT 2025
|
PRIMARY | |||
|
SUB96345
Created by
admin on Mon Mar 31 17:47:33 GMT 2025 , Edited by admin on Mon Mar 31 17:47:33 GMT 2025
|
PRIMARY | |||
|
62182-10-9
Created by
admin on Mon Mar 31 17:47:33 GMT 2025 , Edited by admin on Mon Mar 31 17:47:33 GMT 2025
|
ALTERNATIVE | |||
|
170049
Created by
admin on Mon Mar 31 17:47:33 GMT 2025 , Edited by admin on Mon Mar 31 17:47:33 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
